The development of any new medical product or treatment is complex and heavily regulated process, controlled by so-called National Competent Authorities such as the FDA, the MHRA in the UK and the EMA which oversees the whole EU. These authorities ultimately issue a marketing license based on clinical safety and efficacy information supplied to them by the product developer. This license allows the producer to advertise a product and make claims for its safety and efficacy.
The strategy of HairClone is to develop the various follicle extraction, cryopreservation/banking, cell expansion, cell delivery processes in parallel. This will create a community of scientists, clinicians and patient/clients dedicated to bringing this revolutionary treatment into clinical practice.
Follicle Banking and storage
Investing in HairClone Inc. Equity Based Crowdfunding
Investing in early stage Biotechnology Companies is usually only open to qualified investors. HairClone from the outset has wanted to create a “community” and wanted to enable anyone around the world who is interested in our aims to own shares.